E
Medicenna Therapeutics Corp.
MDNA.TO
TSX
E
Sell
1/15/2025Downgrade
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to E+ from D- on 1/15/2025 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 141.9% from -$1.7M to -$4.12M, EBIT declined 37.25% from -$2.95M to -$4.05M, and earnings per share declined from -$0.0361 to -$0.0397.
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to E+ from D- on 1/15/2025 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 141.9% from -$1.7M to -$4.12M, EBIT declined 37.25% from -$2.95M to -$4.05M, and earnings per share declined from -$0.0361 to -$0.0397.
D
Sell
9/3/2024Upgraded
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D- from E+ on 9/3/2024 due to a significant increase in the total return index, volatility index and solvency index. The quick ratio increased from 1.3 to 2.43.
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D- from E+ on 9/3/2024 due to a significant increase in the total return index, volatility index and solvency index. The quick ratio increased from 1.3 to 2.43.
E
Sell
3/4/2024Downgrade
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to E+ from D- on 3/4/2024 due to a decline in the valuation index.
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to E+ from D- on 3/4/2024 due to a decline in the valuation index.
D
Sell
2/16/2024Upgraded
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D- from E+ on 2/16/2024 due to an increase in the volatility index, total return index and valuation index.
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D- from E+ on 2/16/2024 due to an increase in the volatility index, total return index and valuation index.
E
Sell
3/14/2023Downgrade
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
D
Sell
2/23/2023Upgraded
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D- from E+ on 2/23/2023 due to an increase in the valuation index.
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D- from E+ on 2/23/2023 due to an increase in the valuation index.
E
Sell
2/8/2023Downgrade
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to E+ from D- on 2/8/2023 due to a decline in the growth index, valuation index and total return index. Earnings per share declined from -$0.0108 to -$0.0121.
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to E+ from D- on 2/8/2023 due to a decline in the growth index, valuation index and total return index. Earnings per share declined from -$0.0108 to -$0.0121.
D
Sell
1/4/2023Downgrade
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to D- from D on 1/4/2023 due to a decline in the volatility index and total return index.
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to D- from D on 1/4/2023 due to a decline in the volatility index and total return index.
D
Sell
12/15/2022Upgraded
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D from D- on 12/15/2022 due to an increase in the volatility index.
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D from D- on 12/15/2022 due to an increase in the volatility index.
D
Sell
11/28/2022Downgrade
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to D- from D on 11/28/2022 due to a decline in the total return index and volatility index.
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to D- from D on 11/28/2022 due to a decline in the total return index and volatility index.
D
Sell
11/10/2022Upgraded
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D from D- on 11/10/2022 due to a noticeable increase in the growth index, valuation index and solvency index. Earnings per share increased from -$0.058 to -$0.0108.
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D from D- on 11/10/2022 due to a noticeable increase in the growth index, valuation index and solvency index. Earnings per share increased from -$0.058 to -$0.0108.
D
Sell
10/19/2022Downgrade
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to D- from D on 10/19/2022 due to a decline in the volatility index, valuation index and total return index.
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to D- from D on 10/19/2022 due to a decline in the volatility index, valuation index and total return index.
D
Sell
10/4/2022Upgraded
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D from D- on 10/4/2022 due to an increase in the volatility index and valuation index.
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D from D- on 10/4/2022 due to an increase in the volatility index and valuation index.
D
Sell
9/16/2022Downgrade
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to D- from D on 9/16/2022 due to a decline in the total return index, solvency index and volatility index.
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to D- from D on 9/16/2022 due to a decline in the total return index, solvency index and volatility index.
D
Sell
5/5/2022Upgraded
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index and total return index.
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index and total return index.
D
Sell
4/20/2022Downgrade
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index and solvency index.
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index and solvency index.
D
Sell
11/15/2021Upgraded
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D from D- on 11/15/2021 due to an increase in the growth index.
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D from D- on 11/15/2021 due to an increase in the growth index.
D
Sell
11/8/2021Downgrade
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to D- from D on 11/8/2021 due to a major decline in the total return index, growth index and volatility index. Operating cash flow declined 118.16% from -$1.71M to -$3.72M, EBIT declined 12.2% from -$4.51M to -$5.06M, and earnings per share declined from -$0.088 to -$0.0971.
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to D- from D on 11/8/2021 due to a major decline in the total return index, growth index and volatility index. Operating cash flow declined 118.16% from -$1.71M to -$3.72M, EBIT declined 12.2% from -$4.51M to -$5.06M, and earnings per share declined from -$0.088 to -$0.0971.
D
Sell
5/1/2020Upgraded
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the total return index, volatility index and growth index.
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the total return index, volatility index and growth index.
D
Sell
2/18/2020Downgrade
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to D- from D on 2/18/2020 due to a decline in the growth index. Operating cash flow declined 29.74% from -$1.22M to -$1.58M, EBIT declined 27.17% from -$1.43M to -$1.82M, and earnings per share declined from -$0.0501 to -$0.0545.
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to D- from D on 2/18/2020 due to a decline in the growth index. Operating cash flow declined 29.74% from -$1.22M to -$1.58M, EBIT declined 27.17% from -$1.43M to -$1.82M, and earnings per share declined from -$0.0501 to -$0.0545.
D
Sell
12/11/2019Upgraded
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D from D- on 12/11/2019 due to an increase in the total return index and volatility index.
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D from D- on 12/11/2019 due to an increase in the total return index and volatility index.
D
Sell
10/31/2019Upgraded
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D- from E+ on 10/31/2019 due to an increase in the volatility index and valuation index.
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D- from E+ on 10/31/2019 due to an increase in the volatility index and valuation index.
E
Sell
10/8/2019Downgrade
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to E+ from D- on 10/8/2019 due to a decline in the volatility index and valuation index.
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to E+ from D- on 10/8/2019 due to a decline in the volatility index and valuation index.
D
Sell
9/23/2019Upgraded
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D- from E+ on 9/23/2019 due to an increase in the total return index and volatility index.
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D- from E+ on 9/23/2019 due to an increase in the total return index and volatility index.
E
Sell
8/13/2019Downgrade
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to E+ from D- on 8/13/2019 due to a decline in the efficiency index, solvency index and valuation index. Total capital declined 30.63% from $1.96M to $1.36M, and net income declined 22.63% from -$789.1 to -$967.7.
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to E+ from D- on 8/13/2019 due to a decline in the efficiency index, solvency index and valuation index. Total capital declined 30.63% from $1.96M to $1.36M, and net income declined 22.63% from -$789.1 to -$967.7.
D
Sell
6/12/2019Upgraded
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D- from E+ on 6/12/2019 due to an increase in the total return index and volatility index.
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D- from E+ on 6/12/2019 due to an increase in the total return index and volatility index.
E
Sell
2/15/2019Downgrade
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to E+ from D- on 2/15/2019 due to a decline in the growth index, total return index and volatility index. EBIT declined 90.83% from -$680.2 to -$1.3M, earnings per share declined from -$0.0279 to -$0.0522, and operating cash flow declined 31.3% from -$1.2M to -$1.58M.
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to E+ from D- on 2/15/2019 due to a decline in the growth index, total return index and volatility index. EBIT declined 90.83% from -$680.2 to -$1.3M, earnings per share declined from -$0.0279 to -$0.0522, and operating cash flow declined 31.3% from -$1.2M to -$1.58M.
D
Sell
6/28/2018Upgraded
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D- from E+ on 6/28/2018 due to a noticeable increase in the growth index and efficiency index. Earnings per share increased from -$0.0705 to -$0.0409, EBIT increased 39.75% from -$1.71M to -$1.03M, and net income increased 39.62% from -$1.72M to -$1.04M.
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D- from E+ on 6/28/2018 due to a noticeable increase in the growth index and efficiency index. Earnings per share increased from -$0.0705 to -$0.0409, EBIT increased 39.75% from -$1.71M to -$1.03M, and net income increased 39.62% from -$1.72M to -$1.04M.
E
Sell
6/19/2018Downgrade
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to E+ from D- on 6/19/2018 due to a major decline in the growth index, volatility index and total return index. Operating cash flow declined 43.96% from -$1.73M to -$2.49M, EBIT declined 26.09% from -$1.36M to -$1.71M, and earnings per share declined from -$0.0563 to -$0.0705.
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to E+ from D- on 6/19/2018 due to a major decline in the growth index, volatility index and total return index. Operating cash flow declined 43.96% from -$1.73M to -$2.49M, EBIT declined 26.09% from -$1.36M to -$1.71M, and earnings per share declined from -$0.0563 to -$0.0705.
D
Sell
12/1/2017Upgraded
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D- from E on 12/1/2017 due to an increase in the volatility index and total return index.
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to D- from E on 12/1/2017 due to an increase in the volatility index and total return index.
E
Sell
9/1/2017Upgraded
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to E from E- on 9/1/2017 due to a major increase in the growth index, valuation index and solvency index. Earnings per share increased from -$0.1741 to -$0.069, operating cash flow increased 36.17% from -$2.1M to -$1.34M, and EBIT increased 14.64% from -$1.95M to -$1.67M.
Medicenna Therapeutics Corp. (MDNA.TO) was upgraded to E from E- on 9/1/2017 due to a major increase in the growth index, valuation index and solvency index. Earnings per share increased from -$0.1741 to -$0.069, operating cash flow increased 36.17% from -$2.1M to -$1.34M, and EBIT increased 14.64% from -$1.95M to -$1.67M.
E
Sell
5/31/2017None
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to E- from U on 05/31/2017.
Medicenna Therapeutics Corp. (MDNA.TO) was downgraded to E- from U on 05/31/2017.
